Authorized purpose: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.
Clinical role
Automated brain segmentation and volumetric analysis with user review/editing of WMH candidates before validation and optional longitudinal comparison across exams.
Images and patients
MRI · Brain structures including grey matter, white matter, cerebrospinal fluid, intracranial volume, and white matter hyperintensity candidates
Key limitation
Keep in mind: WMH candidates must be reviewed and, if needed, edited before validation. With contrast-enhanced 3DT1w plus T2w FLAIR, absolute and relative brain-tissue volumes and relative WMH volumes are not reported; absolute WMH measures and WMH longitudinal analysis are displayed. The device is a post-processing plugin for GE Advantage Workstation AW 4.7 or AW Server AWS 3.2 with Volume Viewer Apps 13.0 Ext 4 or higher.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain structures including grey matter, white matter, cerebrospinal fluid, intracranial volume, and white matter hyperintensity candidates Input: A 3D T1-weighted MR image, with an additional T2-weighted FLAIR MR image for WMH segmentation; contrast-enhanced 3DT1w scans are accepted for WMH processing but do not produce all measures.
Who uses it?Intended users: Trained medical professionals, particularly radiology specialists
What does the software produce?Output: Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.
What is its most important limitation?Key limitation: WMH candidates must be reviewed and, if needed, edited before validation. With contrast-enhanced 3DT1w plus T2w FLAIR, absolute and relative brain-tissue volumes and relative WMH volumes are not reported; absolute WMH measures and WMH longitudinal analysis are displayed. The device is a post-processing plugin for GE Advantage Workstation AW 4.7 or AW Server AWS 3.2 with Volume Viewer Apps 13.0 Ext 4 or higher.
Clinical takeaway. Clinical role: Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.
Evidence takeaway. Evidence from the reviewed source record: FDA brain-volumetry validation compared automatic segmentations with manual segmentations on 33 3DT1w MR images across vendors and representative scan settings: Dice was 0.78 +/- 0.05 for CSF, 0.84 +/- 0.02 for GM, 0.86 +/- 0.02 for WM, and 0.97 +/- 0.00 for ICV; absolute differences in relative volumes were 1.8 +/- 1.0, 2.7 +/- 2.0, and 2.8 +/- 1.9 percentage points for CSF, GM, and WM. A WMH set of 45 3DT1w images with corresponding T2w FLAIR produced average Dice 0.61 +/- 0.13; the relative-volume difference was 0.5 +/- 0.5 percentage points over 38 non-contrast cases. These are segmentation and volume endpoints, not sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatic brain-structure labeling, visualization, volumetric quantification, and WMH-candidate assessment as complementary information for trained professionals evaluating MR brain images and preparing quantitative reports.
Automated brain segmentation and volumetric analysis with user review/editing of WMH candidates before validation and optional longitudinal comparison across exams.
A 3D T1-weighted MR image, with an additional T2-weighted FLAIR MR image for WMH segmentation; contrast-enhanced 3DT1w scans are accepted for WMH processing but do not produce all measures.
Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.
WMH candidates must be reviewed and, if needed, edited before validation. With contrast-enhanced 3DT1w plus T2w FLAIR, absolute and relative brain-tissue volumes and relative WMH volumes are not reported; absolute WMH measures and WMH longitudinal analysis are displayed. The device is a post-processing plugin for GE Advantage Workstation AW 4.7 or AW Server AWS 3.2 with Volume Viewer Apps 13.0 Ext 4 or higher.
FDA brain-volumetry validation compared automatic segmentations with manual segmentations on 33 3DT1w MR images across vendors and representative scan settings: Dice was 0.78 +/- 0.05 for CSF, 0.84 +/- 0.02 for GM, 0.86 +/- 0.02 for WM, and 0.97 +/- 0.00 for ICV; absolute differences in relative volumes were 1.8 +/- 1.0, 2.7 +/- 2.0, and 2.8 +/- 1.9 percentage points for CSF, GM, and WM. A WMH set of 45 3DT1w images with corresponding T2w FLAIR produced average Dice 0.61 +/- 0.13; the relative-volume difference was 0.5 +/- 0.5 percentage points over 38 non-contrast cases. These are segmentation and volume endpoints, not sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA brain-volumetry validation compared automatic segmentations with manual segmentations on 33 3DT1w MR images across vendors and representative scan settings: Dice was 0.78 +/- 0.05 for CSF, 0.84 +/- 0.02 for GM, 0.86 +/- 0.02 for WM, and 0.97 +/- 0.00 for ICV; absolute differences in relative volumes were 1.8 +/- 1.0, 2.7 +/- 2.0, and 2.8 +/- 1.9 percentage points for CSF, GM, and WM. A WMH set of 45 3DT1w images with corresponding T2w FLAIR produced average Dice 0.61 +/- 0.13; the relative-volume difference was 0.5 +/- 0.5 percentage points over 38 non-contrast cases. These are segmentation and volume endpoints, not sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Quantib Brain regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K173939
IndependenceIndependence not established
K173939
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K173939. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: A 3D T1-weighted MR image, with an additional T2-weighted FLAIR MR image for WMH segmentation; contrast-enhanced 3DT1w scans are accepted for WMH processing but do not produce all measures.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Quantib Brain is a post-processing plugin for the GE Advantage Workstation/AW Server environment and uses the specified Volume Viewer Apps platform. The FDA packet does not establish a generic PACS, RIS, or EHR interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Quantib Brain as a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms, using Volume Viewer Apps 13.0 Ext 4 or higher. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Quantib™ Brain is post-processing analysis software for the GE Advantage Workstation (AW 4.7) and AW Server (AWS 3.2) platforms using Volume Viewer Apps. 13.0 Ext 4 (or higher)." … "Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Segmentations, visualizations, and absolute/relative volumetric measurements for GM, WM, CSF, and ICV; visualization and quantification of WMH candidates; and longitudinal analysis for brain-tissue and WMH segmentations across multiple exams.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Quantib Brain as a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms, using Volume Viewer Apps 13.0 Ext 4 or higher. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Quantib™ Brain is post-processing analysis software for the GE Advantage Workstation (AW 4.7) and AW Server (AWS 3.2) platforms using Volume Viewer Apps. 13.0 Ext 4 (or higher)." … "Quantib™ Brain is a post-processing plugin for the GE Advantage Workstation (AW 4.7) or AW Server (AWS 3.2) platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Quantib Brain is a post-processing plugin for the GE Advantage Workstation/AW Server environment and uses the specified Volume Viewer Apps platform. The FDA packet does not establish a generic PACS, RIS, or EHR interface.
The 510(k) summary states Quantib Brain is intended to provide the trained medical professional with complementary information for the evaluation and assessment of MR brain images and to aid the trained medical professional in quantitative reporting.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
ACR AI Central provides an exact-submission model card for Quantib Brain; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K173939 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.
Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.